FDA pressed to approve Viagra for women

Mary Bruno

Mary Bruno Jun 27, 2025

Feb 6, 2018

Republish Article

You can republish articles in print or online. Simply copy the HTML below, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline, and credit to Cascade PBS. Republishing of the photos or videos embedded in an article can occur only if the photo or video is a copyright of Cascade Public Media ("CPM") and not of a third party. Photos and videos that are a copyright of CPM are not required to appear in the republished article, but if they are used, they must be embedded where they appear in the original article and must include the attribution to the CPM photographer.

You may reprint in any medium
You may edit only for tense and timeliness
If republishing in print you can edit for length if you follow our print republishing guidelines.
You may write your own headline
Include a byline and shirttail with credit and link to Cascade PBS
Include our tracking pixel
Remove if we ask

          <article>
            <header>
              <hgroup>
                <h1>FDA pressed to approve Viagra for women</h1>
                <h2><p>"Women have waited long enough," argues Even the Score in its fight to compel the Federal Drug Administration to approve a Viagra-like pill for women. The drug in question, flibanserin, was twice rejected by the F.D.A. on effectiveness v. side effects (sleepiness, dizziness, nausea) grounds, explains</p></h2>
              </hgroup>
               <p>By <a href="/author/mary-bruno-crosscut-com/">Mary Bruno</a></p> 
              <p><time datetime="2025-02-04T05:00:00-08:00">Feb 6, 2018</time></p>
            </header>
            <p>"Women have waited long enough," argues <a href="http://eventhescore.org/?ref=dev.cascadepbs.org">Even the Score</a> in its fight to compel the Federal Drug Administration to approve a Viagra-like pill for women. The drug in question, flibanserin, was twice rejected by the F.D.A. on effectiveness v. side effects (sleepiness, dizziness, nausea) grounds, <a href="http://www.nytimes.com/2015/06/01/business/groups-press-fda-to-approve-womens-viagra.html?hp=&action=click&pgtype=Homepage&module=second-column-region&region=top-news&WT.nav=top-news&_r=0&ref=dev.cascadepbs.org">explains the <em>Washington Post</em></a>. The campaign to approve flibanserin is backed by the drug's owner, Sprout Pharmaceutical, along with some women’s groups and the Association of Reproductive Health Professionals. The argument is gender bias: Sex meds for men = 25. Sex meds for women = 0. Where's the fairness? Even the Score's online petition has more than 40,000 signatures. The group also made this cheeky little video for the cause.</p><figure class="kg-card kg-embed-card"><iframe allowfullscreen="allowfullscreen" frameborder="0" height="315" src="https://www.youtube.com/embed/KVdJ5AdmhSQ" width="500"></iframe></figure>
          </article>

"Women have waited long enough," argues Even the Score in its fight to compel the Federal Drug Administration to approve a Viagra-like pill for women. The drug in question, flibanserin, was twice rejected by the F.D.A. on effectiveness v. side effects (sleepiness, dizziness, nausea) grounds, explains the Washington Post. The campaign to approve flibanserin is backed by the drug's owner, Sprout Pharmaceutical, along with some women’s groups and the Association of Reproductive Health Professionals. The argument is gender bias: Sex meds for men = 25. Sex meds for women = 0. Where's the fairness? Even the Score's online petition has more than 40,000 signatures. The group also made this cheeky little video for the cause.

Our members' donations make local journalism happen.

Support once for $1

Support monthly for $7

Cascade PBS Passport
Mossback members-only newsletter
Print Viewer Guide (opt-in)

Support monthly for $25

Invitation to quarterly news and original programming video conference
Annual in-person meet-up with news & programming teams
Special event perks (reduced price or free tickets, cocktails, etc.)

Continue

By Mary Bruno

Mary was Crosscut's Editor-in-Chief and Interim Publisher. In more than 25 years as a journalist, she has worked as a writer, editor and editorial director for a variety of print and web publications,